depot injection boosts antipsychotic compliance in

Submit Demands Online

The qualitative study included four medical workers and five patients who had been treated with fluphenazine haloperidol risperidone given in the form of a long-acting depot injection The data were collected by direct observation analysis of the history of the disease and used semi-structured interview Relapse: Intramuscular depot injection significantly reduced relapse rates compared with oral administration of antipsychotics (RR 0 70 95% CI 0 57 to 0 87) in ten trials (n=1 672) No significant heterogeneity was observed The number needed to treat with

Health professionals' attitudes to depot injection

Evidence suggests that when service users receive their medication via depot injection compliance improves and relapse rates are reduced It is vital that mental health service users are involved in decision making about the mode by which their antipsychotic medication is delivered

The pharmacokinetics of depot antipsychotic medications are such that an intramuscular injection given at intervals of from 1 to 4 weeks will produce adequate plasma concentrations that are sufficient to prevent relapse over the dosage interval Such medication is

1995/8/12Although depot preparations are used extensively in psychiatry few published reports mention the occurrence of complications at the site of injection There are occasional reports of subcutaneous lumps and indurations muscle granulomas medication oozing from and fibrosis at the injection site abscess formation and the accumulation of oil after repeated large volume injection

2018/1/2Fig 1 Main injection sites for antipsychotic long-acting injections: (a) dorsogluteal site (b) ventrogluteal site (c) deltoid site (d) vastus lateralis site Fig 2 The Z-tracking technique Using your non-dominant hand to pull the subcutaneous tissue 2–3 cm sideways (a) pierce the skin at 90 with a dart-like motion (b)

Depot formulations of antipsychotics provide a potential solution to the poor adherence to oral therapies in schizophrenia However there have been few comparative studies on the effectiveness and tolerability of first and second generation depot antipsychotics in a real clinical practice setting The objectives of the present study were to compare safety and outcomes in patients with

Depot Injection Boosts Antipsychotic Compliance in

Home PsychiatrySchizophrenia Latest Articles Depot Injection Boosts Antipsychotic Compliance in Schizophrenia Depot Injection Boosts Antipsychotic Compliance in Schizophrenia The increased compliance achieved with depot administration of antipsychotic medications makes it an attractive alternative to oral administration of antipsychotic drugs to patients with schizophrenia Dr Bruce J

2012/5/23Depot Injection Boosts Antipsychotic Compliance in Schizophrenia Publish date: May 23 2012 By In practice today depot injected antipsychotic medications are secondary treatments used almost like punishment when patients are noncompliant with oral

prescribing information on depot antipsychotics is available from the Summary of Product Characteristics which can be found in the electronic medicines compendium ( ) (See also appendix 2 - Long acting antipsychotic injection

There are only a few depot medications available however and therefore depot olanzapine is a valuable addition to our pharmacopoeia In addition there are also very few rigorous clinical trials of maintenance therapy and therefore those data in the study by Kane et al merit additional examination both for documentation of prevention of relapse and for evidence of longer-term improvement

2017/4/1Results One hundred percent compliance was noticed in licensed indications and dose/frequency within BNF range However 14% patients received poly-pharmacotherapy 86% had regular outpatient review but only 46% had review of side effects

INTRODUCTION: Long-acting depot injections of antipsychotic medications are an important way to monitor treatment noncompliance in patients suffering from schizophrenia Pain and discomfort at the injection site may result in patients' refusal of depot injections

1995/8/12Although depot preparations are used extensively in psychiatry few published reports mention the occurrence of complications at the site of injection There are occasional reports of subcutaneous lumps and indurations muscle granulomas medication oozing from and fibrosis at the injection site abscess formation and the accumulation of oil after repeated large volume injection

Any depot injection compared with equivalent oral formulation 0 41 0 27–0 61 0 0001 0 36 0 17–0 75 0 007 Haloperidol depot injection compared with oral haloperidol 0 27 0 08–0 88 0 03 0 12 0 01–1 13 0 06 Perphenazine depot injection compared with oral 0 32

The Depot Paradox: Long

If approximately 50% of the patients in this population are nonadherent it would stand to reason that about 50% of antipsychotic prescriptions would be for depot formulations But the paradox is that depot antipsychotics play a relatively minor role in the treatment of schizophrenia (8) and American clinicians appear to use these formulations less often than many non-U S counterparts

The pharmacokinetics of depot antipsychotic medications are such that an intramuscular injection given at intervals of from 1 to 4 weeks will produce adequate plasma concentrations that are sufficient to prevent relapse over the dosage interval Such medication is

Relapse despite proven compliance Persistent distressing adverse drug reactions Change of formulation to assist concordance e g switch to depot Risks Associated with Antipsychotic Switches Relapse or destabilisation should the replacement drug be less

Keywords: antipsychotic depot long-acting injection patient survey Introduction Adherence to oral antipsychotic medication is known to be poor with compliance rates estimated at around 40–50% 1 –3 Furthermore many clinicians are not aware of the extent 4

2012/6/1Free Online Library: Depot antipsychotics boost compliance (NEWS) by Clinical Psychiatry News Health care industry Health general Psychology and mental health Antipsychotic agents Antipsychotic drugs Schizophrenia Care and treatment Drug therapy

Relapse despite proven compliance Persistent distressing adverse drug reactions Change of formulation to assist concordance e g switch to depot Risks Associated with Antipsychotic Switches Relapse or destabilisation should the replacement drug be less

Antipsychotic Depot Injections Administration Long-acting antipsychotic depot injections may be administered to adults by deep intramuscular injection They should not be given to children Advantages and disadvantages This form of administration leads to excellent compliance with the medication as there is slow and sustained absorption of the antipsychotic drug from the depot

2017/4/1One hundred percent compliance was noticed in licensed indications and dose/frequency within BNF range However 14% patients received poly-pharmacotherapy 86% had regular outpatient review but only 46% had review of side effects

GUIDELINE FORTHE USE OF DEPOT LONG ACTING INJECTABLE ANTIPSYCHOTICS 4 Approved by MHLD DT August 2018 Ratified by ADTC November 2018 Index 1 0 Aim 2 0 Background 3 0 Definitions 4 0 Prescribing Long Acting Antipsychotic